Apogee Therapeutics, Inc.
A clinical-stage biotechnology company developing antibody medicines for inflammatory and immune diseases such as atopic dermatitis, asthma, and COPD. Founded in 2022 as the first spinout from the Waltham, Massachusetts biotech Paragon Therapeutics, it engineers antibodies with longer half-lives so patients may need injections only every few months instead of weekly. The company went public on the Nasdaq in 2023.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 5.07 Submission of Matters to a Vote of Security Holders · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits